| __timestamp | BioCryst Pharmaceuticals, Inc. | Dynavax Technologies Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 17763000 |
| Thursday, January 1, 2015 | 13047000 | 22180000 |
| Friday, January 1, 2016 | 11253000 | 37257000 |
| Sunday, January 1, 2017 | 13933000 | 27367000 |
| Monday, January 1, 2018 | 29514000 | 64770000 |
| Tuesday, January 1, 2019 | 37121000 | 74986000 |
| Wednesday, January 1, 2020 | 67929000 | 79256000 |
| Friday, January 1, 2021 | 118818000 | 100156000 |
| Saturday, January 1, 2022 | 159371000 | 131408000 |
| Sunday, January 1, 2023 | 213894000 | 152946000 |
Unlocking the unknown
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Dynavax Technologies Corporation and BioCryst Pharmaceuticals, Inc. have shown distinct strategies in optimizing these costs. From 2014 to 2023, BioCryst's SG&A expenses surged by nearly 2,800%, peaking in 2023. Meanwhile, Dynavax saw a more moderate increase of about 760% over the same period.
BioCryst's aggressive spending, particularly from 2020 onwards, suggests a strategic push in marketing and administration, possibly to support new product launches. In contrast, Dynavax's steadier growth in expenses indicates a more controlled approach, balancing expansion with cost efficiency. As these companies navigate the biotech landscape, their SG&A strategies will be pivotal in determining their competitive edge and financial sustainability.
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Dynavax Technologies Corporation
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Dynavax Technologies Corporation
Selling, General, and Administrative Costs: Exelixis, Inc. vs BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and BioCryst Pharmaceuticals, Inc.
Veracyte, Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Arrowhead Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
ImmunityBio, Inc. vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends
Ligand Pharmaceuticals Incorporated vs Dynavax Technologies Corporation: SG&A Expense Trends
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.